Latest Ibandronic acid Stories
Fosamax femur fractures and other side effects addressed in a New York Times article on testing and treatment options for osteoporosis, Bernstein Liebhard LLP reports. New York, NY (PRWEB) August 29, 2012 Fosamax femur fractures and other side effects associated with bisphosphonates continue to raise questions in the medical community, Bernstein Liebhard LLP reports.* On August 27, 2012, the New York Times tackled the issue of testing and treating women for bone loss. According to the...
Parker Waichman LLP has filed a lawsuit on behalf of a South Carolina woman who took Fosamax (alendronate) and suffered from a subtrochanteric fracture in her right thighbone. Fosamax and other bisphosphonates have been linked to atypical femur fractures, which can occur with little or no trauma. New York, New York (PRWEB) July 27, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, has filed a lawsuit alleging...
Parker Waichman LLP has filed a lawsuit alleging that Merck’s Fosamax (alendronate) caused two femur fractures in a Maryland woman. According to the suit, Fosamax and other bisphosphonates can increase the risk of atypical femur fractures. New York, New York (PRWEB) July 24, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a Fosamax lawsuit naming Merck Sharp & Dohme Corp., Merck & Co., Inc. and...
Parker Waichman LLP is filing a lawsuit on behalf of a woman who took Fosamax (alendronate) and suffered a right femur fracture, allegedly due to Fosamax. Although Merck’s Fosamax is used to fight bone loss in patients with osteoporosis and other conditions, the bisphosphonate drug is associated with an increased risk of atypical femur fractures. (PRWEB) July 20, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has...
Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral bisphosphonate. According to the FDA, bisphosphonates may not provide any long-term benefits while simultaneously increasing the risk of atypical femur fractures. New York, New York (PRWEB) July 16, 2012 Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral...
Parker Waichman LLP has filed a lawsuit on behalf of a woman who suffered a left atypical femur fracture, allegedly due to using Fosamax (alendronate). Fosamax is part of a class of drugs known as bisphosphonates, which studies have linked to large bone fractures. New York, NY (PRWEB) July 13, 2012 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Fosamax caused a left femur fracture and...
Ennis & Ennis, PA Summarizes the Latest Fosamax Study that Confirms Long-Term Use of Biphosphonates, such as Fosamax and Boniva, Causes Atypical Femur Fractures (PRWEB) May 26, 2012 After the New England Journal of Medicine published their findings that use of biphosphonates is not deemed beneficial outside of a 3 to 5 year window, the Archives of Internal Medicine have confirmed that prolonged use of the drug increases risk for atypical fractures of the femur. Commonly used brand...
PITTSBURGH, POTTERS BAR, England and MILAN, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its UK and Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, 150 mg. This product is the generic version of Roche's Bonviva(®) Tablets, a treatment for osteoporosis(1). Mylan CEO Heather Bresch said: "This launch represents another day-one generic for Mylan's businesses in the UK and Italy. We are excited to be adding generic...
(Ivanhoe Newswire) -- New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Severe back pain is a common symptom of multiple myeloma—a type of cancer that can cause fractures in long bones and the spine. Bisphosphonate drugs may help to reduce the occurrence of...
Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Multiple myeloma is a type of cancer that grows in and on bones, and can cause fractures in long bones and the spine. Severe back pain is a common symptom. Bisphosphonate drugs may help...
